New compound combats drug-resistant bacteria

Sep 27, 2011

(PhysOrg.com) -- Yale scientists using bits of material from the human immune system have developed a compound that can neutralize or kill several varieties of drug-resistant and other dangerous bacteria. Drug-resistant bacteria are an increasing risk to the health of the world's population. The new compound's ability to kill bacteria in the lab also is promising as a new treatment for infectious diseases.

"The compound is effective in concentrations currently used in drugs and hopefully can be used to combat as well as drug-resistant organisms," said Sidney Altman, Sterling Professor of Molecular, Cellular and Developmental Biology, professor of chemistry, Nobel laureate and senior author of the study.

The research is published the week of Sept. 26 in the .

Altman's lab was attempting to improve upon a new method of suppressing the expression of genes responsible for — i.e., the disease-causing properties — in bacteria.  The method involves using pieces of the RNA that attach to the RNA coded for genes within the cell that are responsible for pathogenesis. The resulting complex, after being exposed to an enzyme inside the cells, then turns off the expression of genes responsible for bacterial survival.

Working in cell culture, the Yale scientists found that they could use a new compound based on a peptide from a human T cell facilitates to deliver this RNA inside many varieties of bacterial cells.  The new compound not only makes bacterial strains more sensitive to existing drugs but also can kill bacteria by targeting genes crucial to cellular survival. The method is 10 to 100 times more effective in targeting bacteria than existing compounds, the scientists estimate.

 "We think this compound will be effective in mice and can go from mice to humans in the future," Altman said.

With Thomas R. Cech, Altman was awarded the Nobel Prize in Chemistry in 1989 for discovery of the catalytic properties of RNA.

Explore further: 'Office life' of bacteria may be their weak spot

Related Stories

Recommended for you

Stem cells use 'first aid kits' to repair damage

2 hours ago

Stem cells hold great promise as a means of repairing cells in conditions such as multiple sclerosis, stroke or injuries of the spinal cord because they have the ability to develop into almost any cell type. ...

Healthy humans make nice homes for viruses

Sep 16, 2014

The same viruses that make us sick can take up residence in and on the human body without provoking a sneeze, cough or other troublesome symptom, according to new research at Washington University School ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Nanobanano
not rated yet Sep 27, 2011
Unfortunately, most research in the area of drug resistant bacteria gets buried...

It's already been two years since I read an article on hear about combining Amoxicillin and Lysine(I think, or some other protien of that nature,) in a drug that was killing MRSA in laboratory experiments. Haven't heard anything about it since though.

The "catch" was that they couldn't figure out how to mass produce the Lysine (or whatever it was).

The other problem with it is there is no financial incentive for the medical industry to actually "cure" disease. If they irradicated Staph, including MRSA along with Strep, then a huge, huge amount of the pharmacy, clinic, ER, and other hospital income would be erased over night...a significant portion of the medical industry would probably go out of business.

So what I expect from this research is about the same. Either it will work, or it won't, and if it does work it will get buried, or reserved only for the filthy rich and government VIPs...